Zusammenfassung
Der klinische Verlauf der axialen Spondyloarthritis (axSpA) ist variabel und durch chronische Rückenschmerzen und extraspinale Manifestationen wie asymmetrische Oligoarthritis, Enthesitis und Daktylitis gekennzeichnet. Nicht wenige Patienten haben auch extraartikuläre Manifestationen an Augen (anteriore Uveitis), Haut (Psoriasis) oder Darm (chronisch entzündliche Darmerkrankungen). Durch die Heterogenität des klinischen Bildes und die Konzentration auf röntgenologisch sichtbare strukturelle Veränderungen in den Sakroiliakalgelenken ist es zu einer zum Teil erheblichen Verzögerung von mehreren Jahren bei der Diagnosestellung gekommen. Ein wichtiger Schritt in Richtung einer verbesserten Früherkennung waren die 2009 publizierten Assessment of SpondyloArthritis International Society (ASAS)-Klassifikationskriterien für axSpA, die neben der Chronizität der initial meist tief sitzenden Rückenschmerzen bei noch relativ jungen Menschen sowohl die Bedeutung der Magnetresonanztomographie als auch die Bestimmung von HLA-B27 in frühen Phasen der Erkrankung betonen. Um die Grundlagen für eine effektive und frühzeitige Therapie der betroffenen Patienten zu gewährleisten, ist dann im Jahr 2014 auf Initiative der Deutschen Gesellschaft für Rheumatologie (DGRh) eine S3-Leitlinie „Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen“ unter Mitwirkungen vieler anderer Fachgesellschaften erstellt worden. Dieser Beitrag gibt einen Überblick über den Inhalt der S3-Leitlinie zur axSpA.
Abstract
The clinical course of axial spondyloarthritis (SpA) is variable and characterized by chronic back pain and extraspinal manifestations, such as asymmetrical arthritis, dactylitis and enthesitis. Extra-articular manifestations in the eyes (anterior uveitis), skin (psoriasis) and intestines (chronic inflammatory bowel disease) are also frequent manifestations in patients with SpA. Due to the heterogeneity of disease manifestations and the partial concentration on structural alterations in the sacroiliac joints visible in X‑ray images, the diagnosis is often delayed for many years. An important step in the direction of improved early recognition of axial SpA was establishment of the Assessment of SpondyloArthritis International Society (ASAS) classification criteria published in 2009, which focused on the initally deep-seated back pain and chronicity in relatively young patients as well as the importance of magnetic resonance imaging and HLA B 27 determination in the early stages of the disease. In order to achieve the foundations for an effective and timely therapy of affected patients, in 2014 on the initiative of the German Society of Rheumatology, S3 guidelines on axial SpA including Bechterew’s disease and early forms were formulated in cooperation with other specialist societies. This article gives an overview of the contents of the S3 guidelines on axial SpA.
Literatur
Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Bohle E et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 1 Introduction/preliminary comments. Z Rheumatol 73(Suppl 2):23–25
Dougados M, Baeten D (2011) Spondyloarthritis. Lancet 377(9783):2127–2137
Kiltz U, Oberschelp U, Schneider E, Swoboda B, Bohm H, Winking M et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 8.6 Invasive therapy. Z Rheumatol 73(Suppl 2):97–100
Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285
Kiltz U, Rudwaleit M, Sieper J, Krause D, Chenot JF, Stallmach A et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 3 Clinical symptoms. Z Rheumatol 73(Suppl 2):28–39
Kiltz U, Rudwaleit M, Sieper J, Krause D, Heiligenhaus A, Pleyer U et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 5 Initial diagnosis/referral strategy. Z Rheumatol 73(Suppl 2):44–48
Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369(9570):1379–1390
van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368
Zink A, Braun J, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis – results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27(3):613–622
Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H et al (2009) The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 60(3):717–727
Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J et al (2012) Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 64(5):1388–1398
Kiltz U, Rudwaleit M, Sieper J, Krause D, Hermann KG, Braun J (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 6 Diagnostics. Z Rheumatol 73(Suppl 2):49–65
Montala N, Juanola X, Collantes E, Munoz-Gomariz E, Gonzalez C, Gratacos J et al (2011) Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. J Rheumatol 38(5):893–897
Song IH, Carrasco-Fernandez J, Rudwaleit M, Sieper J (2008) The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis 67(11):1535–1540
Dougados M, Gueguen A, Nakache JP, Velicitat P, Zeidler H, Veys E et al (1999) Clinical relevance of C‑reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 26(4):971–974
Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H et al (1999) Relative value of erythrocyte sedimentation rate and C‑reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26(4):980–984
Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Bohle E et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 8 Therapy, 8.1 Treatment concept, 8.2 Therapy targets and strategy. Z Rheumatol 73(Suppl 2):69–70
Kiltz U, Mau W, Smolenski U, Repschlager U, Bohle E, Stemmer M et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 8.3 Nonpharmaceutical therapeutic measures. Z Rheumatol 73(Suppl 2):71–77
Kiltz U, Sieper J, Kellner H, Krause D, Rudwaleit M, Chenot JF et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures. Z Rheumatol 73(Suppl 2):78–96
van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R et al (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70(6:905–908
Kiltz U, Sieper J, Braun J (2013) ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis : evaluation of the 2010 update in the German-speaking area. Z Rheumatol 72(1:81–88
Chen J, Liu C (2005) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2:CD004800
Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K et al (2006) Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 65(9):1147–1153
Chen J, Liu C, Lin J (2006) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD004524
Vander Cruyssen B, Munoz-Gomariz E, Font P, Mulero J, de Vlam K, Boonen A et al (2010) Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford) 49(1):73–81
Kiltz U, Mau W, Repschlager U, Bohle E, Braun J (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 8.7 Rehabilitation. Z Rheumatol 73(Suppl 2):101–103
Kiltz U, Mau W, Repschlager U, Bohle E, Braun J (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 9 International classification of functioning, disability and health (ICF). Z Rheumatol 73(Suppl 2):104–108
Boonen A, Braun J, van der Horst Bruinsma IE, Huang F, Maksymowych W, Kostanjsek N et al (2010) ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis 69(1):102–107
Kiltz U, Stemmer M, Braun J (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 10 Patient information. Z Rheumatol 73(Suppl 2):109–111
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P et al (2015) Secukinumab, an Interleukin-17A Inhibitor. N Engl J Med 373(26):2534–2548
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
Die bestehenden Interessenskonflikte der Leitlinienautoren für die Erstellung der S3-Leitlinie sind im Leitlinien-Report ausführlich dargestellt.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Additional information
Redaktion
A. Zink, Berlin
B. Hellmich, Kirchheim-Teck
Die Langfassung der Leitlinie kann unter http://www.awmf.org/leitlinien/detail/ll/060-003.html eingesehen werden.
Rights and permissions
About this article
Cite this article
Kiltz, U., Rudwaleit, M., Sieper, J. et al. Evidenzbasierte Empfehlung zur Diagnostik und Therapie der axialen Spondyloarthritis. Z Rheumatol 76, 111–117 (2017). https://doi.org/10.1007/s00393-016-0232-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-016-0232-x